E
Oncolytics Biotech Inc. ONCY
$0.89 $0.011.66% NASDAQ
Recommendation
Prev Close
$0.88
Volume
380,969
Avg Vol (90D)
966,172
Market Cap
$93.41M
Dividend & Yield
--
52-Week Range
$0.33 - $1.51
P/E (TTM)
--
EPS (TTM)
-$0.28
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
12/3/2025 - Globe Newswire
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
12/3/2025 - Zacks Investment Research
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Brokerages
12/2/2025 - MarketBeat
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays
11/20/2025 - TipRanks Financial Blog
Oncolytics Biotech Provides Update on Special Meeting of Shareholders
11/20/2025 - Business Wire
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst
11/20/2025 - MarketBeat
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital
11/20/2025 - TipRanks Financial Blog
Oncolytics Biotech (ONCY) Advances with FDA-Approved Study Design
11/19/2025 - GuruFocus
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
11/19/2025 - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)
11/19/2025 - TipRanks Financial Blog
Oncolytics Biotech Inc
11/19/2025 - MENAFN.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
11/19/2025 - Globe Newswire
Oncolytics Biotech Aligns with FDA for Pivotal Pancreatic Cancer Study
11/19/2025 - TipRanks Financial Blog
Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
11/19/2025 - Business Wire
Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers
11/17/2025 - TipRanks Financial Blog
Oncolytics Biotech (ONCY) Price Target Raised by HC Wainwright ONCY Stock News
11/17/2025 - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Sell" Rating by Wall Street Zen
11/16/2025 - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
11/14/2025 - MarketBeat
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by Analysts
11/7/2025 - MarketBeat
Oncolytics Biotech (ONCY) to Release Earnings on Tuesday
11/5/2025 - MarketBeat
Oncolytics Biotech Inc
11/4/2025 - MENAFN.com
Oncolytics Biotech Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
11/4/2025 - Business Wire
What is HC Wainwright's Estimate for ONCY Q1 Earnings?
11/1/2025 - MarketBeat
Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
10/28/2025 - CNW Group - News Releases
Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
10/28/2025 - PR Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$25.02M
EBIT (TTM)
-$25.08M
Net Income (TTM)
-$25.30M
Balance Sheet
Total Assets (Q)
$10.81M
Total Debt (Q)
$599.50K
Total Liabilities (Q)
$10.73M
Book Value Per Share (Q)
$0.0008
Cash Flow
Cash from Operations (TTM)
-$18.92M
Cash from Investing (TTM)
-$9.40K
Cash from Financing (TTM)
$13.38M
Net Change in Cash (TTM)
-$5.20M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Loading...
Beta
0.41
7-Day Total Return
-10.54%
30-Day Total Return
-19.41%
60-Day Total Return
-35.64%
90-Day Total Return
-17.93%
Year to Date Total Return
-3.79%
1-Year Total Return
1.44%
2-Year Total Return
-36.55%
3-Year Total Return
-53.65%
5-Year Total Return
-75.36%
52-week Low
Jun 06, 2025 - $0.33
52-week High
Sep 29, 2025 - $1.51
Valuation
Market Cap
$93.41M - Micro Cap
Enterprise Value
$85.14M
Price/Sales (TTM)
--
Price/Book (Q)
1,100.00
Dividends and Shares
Shares Outstanding
101.32
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
oncolyticsbiotech.com
Phone Number
403 670 7377
Address
322 11th Avenue SW
Calgary, AB T2R 0C5
Country
Canada
Year Founded
1998
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an... more
NASDAQ 12/03/2025 2:07PM Eastern Quotes delayed